JUN 16, 2021 7:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

The paradigm of lung cancer: from therapy selection to resistance monitoring

Sponsored by: Agilent
Speaker
  • Full Professor of Pathology and Director of the Inter-Departmental Center of Advanced Molecular Diagnostics and Innovative Therapies, University of Chieti-Pescara, Italy
    Biography
      Dr Antonio Marchetti is Full Professor of Pathology and Director of the Inter-Departmental Center of Advanced Molecular Diagnostics and Innovative Therapies, University of Chieti-Pescara, Italy. He’s Coordinator of the Italian Group of Molecular Pathologists and a Member of the European Organization for Research and Treatment of Cancer (EORTC) and the International Association for the Study of Lung Cancer (IASLC). He served as Member of the National Biotechnology and Biosecurity Committee, Italian Government. His main research interests lay in the field of molecular characterization of solid tumors, development and application of sensitive molecular techniques for mutation detection in tissue and plasma, detection of occult metastasis/minimal residual disease, and early cancer diagnosis.

    Abstract
    Date:  June 16, 2021
    Time: 7:00am (PDT),  10:00am (EDT)
     
    Non-small cell lung cancer (NSCLC) has become an important example of precision medicine among solid tumor malignancies. Next-generation sequencing panels have proven to be powerful tools for multi-marker analysis and here, we describe the use of an all-in one lung panel to detect mutations in lung tumor samples. In addition, we have been able to identify specific mutations in liquid biopsies—such as CNVs and gene fusions—that are important drivers of resistance in NSCLC.
     
    Learning Objectives
    • Explain how lung cancer treatment has changed in the context of personalized medicine
    • Describe the approach of detecting DNA fusions using the SureSelect hybrid capture-based targeted NGS
    • Share experience in implementing an automated NGS workflow with the Magnis NGS Prep System and SureSelect Cancer All-In-One panels

     

    For Research Use Only. Not for use in diagnostic procedures.
     
    Webinars will be available for unlimited on-demand viewing after live event.
     
     

    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    MAR 18, 2021 8:00 AM PDT
    C.E. CREDITS
    MAR 18, 2021 8:00 AM PDT
    DATE: March 18, 2021 TIME: 8:00am PDT Sequencing of bulk cells, single cells, and nuclei is opening doors in the understanding of complex biological processes....
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    Loading Comments...
    Show Resources
    Event Countdown
    • 0 Days
    • 0 Hours
    • 0 Minutes
    • 0 Seconds
    Attendees
    • See more